Skip to Main Content
Table 3—

Clamp-derived measures of insulin sensitivity and β-cell secretory capacity and clearance

Hyperglycemic clampEuglycemic clamp
M (mg · kg−1 · min114.1 ± 6.5 14.7 ± 8.2 
SIClamp (mg · kg−1 · min−1 per μU/ml) 16.7 ± 14.3 3.5 ± 3.5 
First-phase insulin (pmol/l) 648.6 ± 658.7  
Steady-phase insulin (pmol/l) 974.4 ± 663.7  
First-phase C-peptide (nmol/l) 2.2 ± 1.2  
Steady-phase C-peptide (nmol/l) 3.7 ± 1.2  
MCR of insulin (mg · kg−1 · min−1 per μU/ml)  0.106 ± 0.033 
First-phase C-peptide/insulin molar ratio 4.8 ± 2.0  
Steady-phase C-peptide/insulin molar ratio 4.8 ± 1.8  
Total % FFA suppression  77.6 ± 16.0 
First-phase FFA suppression 4.9 ± 23.1  
Steady-phase % FFA suppression 54.7 ± 18.0  
Hyperglycemic clampEuglycemic clamp
M (mg · kg−1 · min114.1 ± 6.5 14.7 ± 8.2 
SIClamp (mg · kg−1 · min−1 per μU/ml) 16.7 ± 14.3 3.5 ± 3.5 
First-phase insulin (pmol/l) 648.6 ± 658.7  
Steady-phase insulin (pmol/l) 974.4 ± 663.7  
First-phase C-peptide (nmol/l) 2.2 ± 1.2  
Steady-phase C-peptide (nmol/l) 3.7 ± 1.2  
MCR of insulin (mg · kg−1 · min−1 per μU/ml)  0.106 ± 0.033 
First-phase C-peptide/insulin molar ratio 4.8 ± 2.0  
Steady-phase C-peptide/insulin molar ratio 4.8 ± 1.8  
Total % FFA suppression  77.6 ± 16.0 
First-phase FFA suppression 4.9 ± 23.1  
Steady-phase % FFA suppression 54.7 ± 18.0  

Data are means ± SD.

Close Modal

or Create an Account

Close Modal
Close Modal